{
    "Trade/Device Name(s)": [
        "ADVIA Centaur\u00ae Testosterone II (TSTII)",
        "ADVIA Centaur\u00ae SHBG"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K191533",
    "Predicate Device Reference 510(k) Number(s)": [
        "K151986"
    ],
    "Regulatory Class": "Class I, reserved",
    "Product Code(s)": [
        "CDZ"
    ],
    "Summary Letter Date": "September 20, 2019",
    "Summary Letter Received Date": "June 10, 2019",
    "Submission Date": "June 7, 2019",
    "Regulation Number(s)": [
        "21 CFR 862.1680"
    ],
    "Regulation Name(s)": [
        "Testosterone test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Testosterone",
        "Sex hormone-binding globulin (SHBG)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ADVIA Centaur\u00ae XP system"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescence immunoassay"
    ],
    "Methodologies": [
        "Competitive immunoassay",
        "Sandwich immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for re-standardized ADVIA Centaur\u00ae Testosterone II (TSTII) and new reference intervals for ADVIA Centaur\u00ae SHBG using chemiluminescence immunoassays on the ADVIA Centaur XP system",
    "Indications for Use Summary": "ADVIA Centaur\u00ae Testosterone II (TSTII): quantitative determination of total testosterone in human serum and plasma to aid in diagnosing and treating disorders involving androgens; ADVIA Centaur\u00ae SHBG: quantitative determination of SHBG in human serum and plasma to aid in diagnosis of androgen disorders",
    "fda_folder": "Clinical Chemistry"
}